立即注册找回密码

QQ登录

只需一步,快速开始

微信登录

微信扫一扫,快速登录

手机动态码快速登录

手机号快速注册登录

搜索

图文播报

查看: 3950|回复: 0

[仪器信息] 狼来了!罗氏诊断推出自主研发血球分析仪Cobas m 511!

[复制链接]
发表于 2017-1-25 22:01 | 显示全部楼层 |阅读模式

登陆有奖并可浏览互动!

您需要 登录 才可以下载或查看,没有账号?立即注册 微信登录 手机动态码快速登录

×
核心提示:罗氏推出 Cobas m 511 血球分析仪,进入了血球领域的新时代!


1月23日,罗氏公司称其最新的 cobas m 511 一体化血液分析仪已经在接受CE安全认证的国家上市,这标志着罗氏诊断通过自有成熟的产品体系,进入了血液检测领域的新纪元。

目前,血液检测需要患者提供较大量的血量,并需要通过多个仪器的检测才能得到全套验血结果,这种检测既需要较高的人力成本还很耗时,并由于血片结果难以阐明而可能会出现前后不一致的结果。

640.webp.jpg

通过Bloodhound® 技术,cobas m 511 一体化血液分析仪有望变革验血业务。它是一台三合一的高效的血片制备、着色和分析系统(整合数字形态分析仪、细胞计数仪及分类仪),让实验室能够节省空间、时间和金钱。它只需30微升的血样就能得到全套验血结果,包括形态评估,所以还适合那些血量尤为珍贵的患者。

罗氏诊断的CEO Roland Diggelmann 表示:随着这套检测仪器的使用,血液系统疾病(贫血及白血病)患者将会更快和更准确的获得诊断结果,通过为消费者提供整合及高效的实验室解决方案,我们也因此进入了血液检测行业的新的领域。

相对于目前的检测仪器,cobas m 511 通过对白细胞、红细胞与血小板的识别、计数、分离及分类,并提供细胞的数字成像,可以得到更加精确及一致的检测结果,医疗技术人员现在可以集中时间去识别和分类患者血样的非正常细胞。cobas m 511的自动化与数字化可以降低对人工显微镜检查的需求,医生可以将具有挑战性的案例通过世界范围内的共享去解决,同时检测结果的快速获得也为患者的治疗带来更大的机会。

640.webp (1).jpg
640.webp (2).jpg

附原文:
Roche enters a new era in haematology testing, with the launch of the new cobas m 511 analyser

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that its new, dedicated haematology testing solution, the cobas m 511 integrated haematology analyser, is now available for countries accepting the CE Mark*. This launch marks the entry for Roche Diagnostics in the haematology market, with a Roche developed system.

Currently, haematology testing requires a larger blood sample from a given patient, which needs to be run across several different systems in order to get the full set of results. This is labour- and time-intensive, and potentially provides inconsistent results, as slide images are difficult to interpret.

Featuring Bloodhound® technology, the cobas m 511 addresses the challenges of haematology testing by combining the three components of the process: a digital morphology analyser, cell counter and classifier into one streamlined solution which prepares, stains and analyses microscopy blood slides.

“With this launch, patients will benefit from a faster and more accurate diagnosis of blood diseases, as diverse as anemia and leukemia”, said Roland Diggelmann, CEO of Roche Diagnostics. “We are entering a new area of innovation with Roche in haematology testing, supporting customers with integrated and efficient laboratory solutions, which deliver increased medical value”.

The cobas m 511 provides greater accuracy and consistency of results, compared to current technologies, by identifying, counting, isolating and categorising white blood cells, red blood cells and platelets, then presenting the digital images of all these cell types. Medical technologists can now concentrate their time on finding and classifying abnormal cells within patient samples. This automation and digitalization reduces the need for resource-intensive manual microscope reviews, supports clinicians to share challenging cases around the world and enables the delivery of quicker results, which ultimately aid patient diagnoses.

About Haematology

There are more than 150 identified haematology related diseases, also called blood diseases, blood disorders or haematological disorders. They can be either benign (noncancerous) or malignant (cancerous) and are broadly classified according to the different components of the blood that are affected: red blood cells, white blood cells, platelets and blood plasma.

The burden of blood disorders is very high, not only for patients but for society as a whole. Recent studies estimated that, in Europe, 80 million people suffer from haematological disorders and the economic impact of blood disorders in Europe amounts to EUR  23 billion per year, mostly in healthcare expenditure. Improved diagnosis is a key factor to counteract the rise on this economic burden for healthcare and society.1

About the cobas m 511 and Bloodhound® technology

The cobas m 511, uses a unique approach to enter the new field of digital haematology through patented Bloodhound® technology for printing, staining and imaging. This technology uses only 30μL of blood to print a monolayer onto the slide, stains with an improved method for further analysis of the morphology and enables classification of cells displayed on a Viewing Station.

Contrary to the commonly used indirect methods in blood analysis today - primarily impedance and flow cytometry - the cobas m 511 images individual cells directly. Based on these direct images, the Bloodhound® technology counts, analyses morphology and then classifies every cell in the viewing area to provide a standard complete blood count (CBC) and 5-part differential and reticulocyte count. While haematologists will continue to have the option of looking at slides under their microscopes; the cobas m 511 provides cell-by-cell images that, in many cases, may eliminate the need for microscopic review.

About Roche

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives.

Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.

Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. Twenty-nine medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry eight years in a row by the Dow Jones Sustainability Indices.

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2015 employed more than 91,700 people worldwide. In 2015, Roche invested CHF 9.3 billion in R&D and posted sales of CHF 48.1 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law.

*Local product availability may vary independently from CE Mark approval. The cobas m 511 integrated hematology analyser is not available in countries with previously agreed 3rd party vendor agreements.

References
1. Green T, Bron D, Chomienne C, Duyvené de Wit T, de Haas F, Engert A, Hagenbeek A, Jäger U, MacIntyre E, Muckenthaler M, Smand C, Sonneveld P. Costs of haematological disease high and rising. Lancet Haematol 2016 http://press.thelancet.com/HaemComments.pdf

来源:麦科田医疗

楼主热帖
回复

使用道具 举报

发表回复

您需要登录后才可以回帖 登录 | 立即注册 微信登录 手机动态码快速登录

本版积分规则

关闭

官方推荐 上一条 /3 下一条

快速回复 返回列表 客服中心 搜索 官方QQ群 洽谈合作
快速回复返回顶部 返回列表